Indeed, several of the type 2 diabetes treatments target β‐cells to induce insulin secretion such as sulfonylureas, dipeptidyl peptidase 4 inhibitors (DPP4i) as well as drugs that act as GLP‐1R and GPR40 agonists.[112]. Here, DPP4 is linked to type 2 diabetes mellitus.